|
|
 |
|
Viewing report
|
|
|
|
BioMarin Pharmaceutical Inc.: SWOT Analysis & Company Profile
Business Review, Sep 2010, Pages: 27
Synopsis
Business Review’s BioMarin Pharmaceutical Inc. contains a company overview, key facts, locations and subsidiaries, news and events as well as a SWOT analysis of the company.
Summary
This SWOT Analysis company profile is a crucial resource for industry executives and anyone looking to quickly understand the key information concerning BioMarin Pharmaceutical Inc.’s business.
Business Review’s “BioMarin Pharmaceutical Inc. SWOT Analysis & Company Profile” reports utilize a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.
Business Review strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Scope
- Examines and identifies key information and issues about (BioMarin Pharmaceutical Inc.) for business intelligence requirements
- Studies and presents BioMarin Pharmaceutical Inc.’s strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
- The profile contains business operations, the company history, major products and services, prospects, key competitors, structure and key employees, locations and subsidiaries.
Reasons To Buy
- Quickly enhance your understanding of the company.
- Obtain details and analysis of the market and competitors as well as internal and external factors which could impact the industry.
- Increase business/sales activities by understanding your competitors’ businesses better.
- Recognize potential partnerships and suppliers.
- Obtain yearly profitability figures
Key Highlights
BioMarin Pharmaceutical Inc. (BioMarin) is an US based pharmaceutical company, principally engaged in the development and commercialization of innovative biopharmaceuticals for serious diseases and medical conditions. BioMarin’s product portfolio includes four approved products namely Naglazyme, Aldurazyme, and Kuvan and Firdapse. The products that are under clinical trials are PEG-PAL, GALNS and BMN-195. The company is also working on a preclinical study of BMN-185 and BMN-103. The company also has operations in some of the major European countries and Latin America along with the US which it manages with its subsidiaries in Ireland and Argentina. The company is headquartered in California, the US.
|
|
|
|
